📈
📈 Business
AstraZeneca Stock Drops 9% After Heart Drug Trial Fails to Meet Primary Endpoint
Shares in AstraZeneca, the UK's largest drugmaker, fell 9% on Thursday after the company announced that a late-stage clinical trial of its heart drug failed to meet its primary endpoint. The result is a major setback for the British pharmaceutical giant, which had high hopes for the therapy. No further details about the specific drug were given.
Comments
No comments yet
Comments
No comments yet — be the first to weigh in 👇
No comments yet. Be the first!